Medicinal composition for preventing or alleviating diabetes and complications thereof

A technology for diabetes and complications, applied in the field of pharmaceutical compositions, can solve the problems of low bioavailability, poor effect, inability to effectively prevent or slow down diabetes, etc.

Inactive Publication Date: 2017-10-31
NAT CHIAYI UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Studies have pointed out that the administration of resveratrol can reduce the concentration of blood sugar, but according to the report, the bioavailability of resveratrol in animals is low, and the peanut p-styrene derivatives that also belong to the stilbenes have been reported to have Removal of free radicals (reactive oxygen species; ROS), anti-oxidation and life extension effects
[0005] Although many drugs have been developed to treat diabetes, they are not effective in the actual prevention or treatment of diabetes, because the pathogenesis of diabetes is complicated. Diabetic patients are prone to other diseases due to long-term high blood sugar in their blood, so they cannot be effectively prevented. or slow down diabetes and its complications

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition for preventing or alleviating diabetes and complications thereof
  • Medicinal composition for preventing or alleviating diabetes and complications thereof
  • Medicinal composition for preventing or alleviating diabetes and complications thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0048] Example 1: Establishment of an in vitro cell platform

[0049] 1. Cultivating kidney epithelial cell line MDCK

[0050] The kidney epithelial cell line MDCK (Canine Kidney Epithelial Cell Line Madin-Darby caninekidney; MDCK; for example, obtained from the Taiwan Biological Resources Conservation and Research Center with the deposit number CCRC60004; ATCC CCL-34), according to the Taiwan Food Industry Development Institute Biological Resources Conservation And recommended by the research center, cultured in Fetal Bovine Serum (FBS) containing 10%, 1.2mg / mL NaHCO 3 , 0.1mg / mL streptomycin (streptomycin) n and 0.5mg / mL ampicillin (ampicillin), pH 7.4 MEM minimum essential medium (minimal essential medium, MEM; BRL, Grand Island, NY) culture medium, placed in 5% CO 2 , Cultivation in a constant temperature incubator (NUAIR NU4500, USA) at 37°C, and replace with fresh culture medium every 2 to 3 days. When the cells grow to about 90% full, wash the cells gently with Phosphate Bu...

Embodiment 2

[0063] Example 2: In vitro evaluation method of medical composition containing soybean isoflavones and peanut p-styrene derivatives

[0064] This example is to use the in vitro high-concentration glucose culture solution treatment platform established in Example 1 to evaluate that the pharmaceutical composition containing soybean isoflavones and peanut p-styrene derivatives in Example 1 reduces the amount of blood in the kidney epithelial cell line MDCK cells. The amount of free radicals produced.

[0065] 1. Assess the amount of free radicals produced in cells

[0066] Using anhydrous DMSO, 2,7-dichlorofluorescein-3',6'-diacetate (2,7-dichlorofluoresceindiacetate; H2DCF-DA; Invitrogen, USA) was prepared into a 10mM / μL solution. After washing the MDCK cell line with PBS, adding PBS containing a final concentration of 10μM H2DCF-DA, reacting for 30 minutes in a constant temperature incubator at 37°C, washing with PBS, adding MEM without phenol red ( BRL, Grand Island, NY). After rea...

Embodiment 3

[0070] Example 3: Using animal experiments to evaluate the effect of medical composition in preventing or reducing diabetes and its complications

[0071] This example uses living experimental animals to evaluate the effect of the pharmaceutical composition containing soybean isoflavones and peanut p-styrene derivatives of Example 1 in preventing or reducing diabetes and its complications in vivo.

[0072] 1. Establish experimental animals

[0073] 1.1 Animal feeding

[0074] 48 6-week-old Specific Pathogen-Free (SPF) mice (strain: C57BL / 6); source: National Laboratory Animal Center), each group has 6 male mice and 6 female mice Rats were randomly grouped as shown in Table 2:

[0075] Table 2

[0076]

[0077]

[0078] C57BL / 6 mice were raised in a positive pressure environment free of specific pathogens. The temperature was controlled at 24°C and maintained at a 12-hour light-dark cycle. Feed and water supply were not restricted during the breeding period. The breeding conditions of C...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a medicinal composition for preventing or alleviating diabetes and complications of diabetes. The medicinal composition comprises a plant source mixture containing soy isoflavone and an arachidonic acid derivative at the weight ratio being (1:1) to (10:1). Therefore, the medicinal composition for preventing or alleviating diabetes and complications of diabetes can reduce the content of free radicals of the kidney epithelial cells in the in-vitro high-glucose environment, and can promote the insulin concentration, reduce the contents of blood sugar and blood fat, reduce the activity of alanine aminotransferase, reduce inflammatory response and the like in vivo, so that diabetes and complications of diabetes can be prevented or retarded.

Description

Technical field [0001] The present invention relates to a medicinal composition, in particular to a medicinal composition and a medicinal composition used to prevent or slow down diabetes and its complications. Background technique [0002] With the aging of the population and changes in lifestyle and dietary patterns, the number of patients with diabetes (Diabetes) has been increasing in recent years. It is reported that there were 382 million diabetic patients worldwide in 2013. Diabetes is the highest in Taiwan. The top four causes of death among Chinese people. Diabetes is a metabolic disease, which is characterized by long-term blood sugar higher than the standard value, and the cause is that insulin secretion or function is defective, leading to metabolic disorders. Diabetes patients are prone to other diseases due to long-term blood containing high blood sugar. Common diabetes treatment methods include diet control, exercise therapy, and drug therapy. [0003] Soy isoflav...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61K31/05A61P3/10A61P3/06A61P5/50A61P29/00A61P43/00
CPCA61K31/05A61K31/352A61K36/48A61K2300/00
Inventor 翁博群陈立耿陈俊宪翁炳孙
Owner NAT CHIAYI UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap